Details About Generic Salt ::  Bismuth

Main Medicine Class:: Antidiarrheal   

(BISS-muth sub-suh-LIS-ih-late)

Bismatrol, Bismatrol Extra Strength, Pepto-Bismol Maximum Strength, Pepto-Bismol,  Pink Bismuth, PMS-Bismuth Subsalicylate Liquid

Class: Antidiarrheal

Drugs Class ::

 Action Produces antisecretory and antimicrobial effects; may have anti-inflammatory effect.

Indications for Drugs ::

 Indications Treatment of indigestion without causing constipation, nausea, abdominal cramps; diarrheal control, including traveler’s diarrhea. Unlabeled use(s): Treatment of recurrent ulcers, chronic infantile diarrhea, gastroenteritis associated with Norwalk virus; prevention of traveler’s diarrhea.

Drug Dose ::

 Route/Dosage

ADULTS: PO 2 tablets (262 mg each) or 30 ml suspension q 30 to 60 min prn (maximum 8 doses/day). CHILDREN 9–12 YR: PO 1 tablet or 15 ml suspension q 30 to 60 min prn (maximum 8 doses/day). CHILDREN 6–9 YR: PO  tablet or 10 ml suspension q 30 to 60 min prn (maximum 8 doses/day). CHILDREN 3–6 YR: PO  tablet or 5 ml suspension q 30 to 60 min prn (maximum 8 doses/day). CHILDREN < 3 YR: Consult physician.

Contraindication ::

 Contraindications Viral illness such as chickenpox or influenza in patients < 18 yr.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: May cause impaction. Debilitated patients: May cause impaction.

Drug Side Effects ::

 Adverse Reactions

EENT: Tinnitus; discoloration of tongue. GI: Discoloration of stools; impaction.

Drug Mode of Action ::  

 Action Produces antisecretory and antimicrobial effects; may have anti-inflammatory effect.

Drug Interactions ::

 Interactions

Aspirin or other salicylates: May cause salicylate toxicity. Corticosteroids: May decrease effectiveness. Insulin: Drug may increase glucose-lowering effect of insulin. Methotrexate: Drug may increase effects and toxicity of methotrexate. Spironolactone: Drug may interfere with diuretic effect. Sulfinpyrazone: Drug may interfere with uricosuric effect. Tetracyclines: Bismuth subsalicylate may reduce GI absorption of tetracyclines and diminish their effectiveness. Valproic acid: Drug may increase free fraction of valproic acid, leading to toxicity.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess patient for risk of Reye’s syndrome.
• Determine if patient is taking otc medications for colds, fever, and pain; many contain salicylates, which may produce additive toxicity.
• Observe for discoloration of stool produced by drug (may mask GI bleeding).
• Discontinue use when symptoms subside.

Drug Storage/Management ::

 Administration/Storage

• Tablets may be crushed, chewed, or allowed to dissolve in mouth. Do not allow patient to swallow whole.
• Before administering, shake suspension well.
• Store at room temperature.
• Protect from light.

Drug Notes ::

 Patient/Family Education

• Counsel patient to maintain adequate fluid intake (2 to 3 L/day) to prevent dehydration.
• Instruct patient to notify physician if diarrhea is accompanied by high fever or continues > 2 days or if abdominal pain occurs.
• Advise patient not to use medication if concurrent viral illness is present.
• Instruct patient to consult with physician before taking drug if concurrently taking other salicylates, anticoagulants or medications for diabetes or gout.
• Instruct patient to inform physician regarding bismuth subsalicylate administration before any scheduled radiologic studies or stool examinations.
• Inform patient of possibility of salicylate toxicity and associated symptoms, and instruct patient to notify physician if these symptoms occur.
• Explain that stools may become black or gray and tongue may darken.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.